Literature DB >> 11605058

Cyclooxygenase-2 level and culture conditions influence NS398-induced apoptosis and caspase activation in lung cancer cells.

H C Chang1, C F Weng.   

Abstract

Cyclooxygenases (COXs) catalyze the synthesis of prostaglandins (PGs) from arachidonic acid. Overexpression of COX-2 is frequently found in human cancers and is suggested to play an important role in tumorigenesis. Recent studies indicated that COX-2 inhibitors exert potent anti-cancer effects on a number of cancers. Interestingly, some COX-2 inhibitors potently induce apoptosis, while other COX-2 inhibitors primarily induce growth inhibition. Therefore, there is a variability in the effects that different COX-2 inhibitors have on cancer cells. In this study, we demonstrated that induction of apoptosis of high COX-2-expressing A549 lung cancer cells by a specific COX-2 inhibitor NS398 was observed in cells cultured under serum-free condition. However, this drug induced G1 growth arrest rather than apoptosis in A549 cells maintained in 10% serum medium. Conversely, low COX-2-expressing H226 lung cancer cells were resistant to NS398-induced apoptosis under both serum-free and serum-containing conditions. Moreover, our results showed that NS398-induced apoptosis is associated with activation of caspase-3, a cysteine protease that plays a crucial role in the execution phase of apoptosis. These results suggest that the cytotoxic effect of COX-2 inhibitors on cancer cells may be influenced by extracellular environments and the anti-cancer action of these inhibitors in vivo needs careful evaluation. Additionally, a correlation between the level of COX-2 expression and the extent of apoptosis induced by COX-2 inhibitors was found.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11605058     DOI: 10.3892/or.8.6.1321

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  8 in total

1.  Luteolin supplementation adjacent to aspirin treatment reduced dimethylhydrazine-induced experimental colon carcinogenesis in rats.

Authors:  Neamt H A Osman; Usama Z Said; Ahmed M El-Waseef; Esraa S A Ahmed
Journal:  Tumour Biol       Date:  2014-10-24

2.  Relationship between epidermal growth factor receptor (EGFR) mutation and serum cyclooxygenase-2 Level, and the synergistic effect of celecoxib and gefitinib on EGFR expression in non-small cell lung cancer cells.

Authors:  Na Li; Huanhuan Li; Fan Su; Jing Li; Xiaoping Ma; Ping Gong
Journal:  Int J Clin Exp Pathol       Date:  2015-08-01

3.  Formulation and evaluation of aerosolized celecoxib for the treatment of lung cancer.

Authors:  Alfred Haynes; Madhu Sudhan Shaik; Abhijit Chatterjee; M Singh
Journal:  Pharm Res       Date:  2005-03       Impact factor: 4.200

4.  Effect of NS-398, a cyclooxygenase-2 selective inhibitor, on the cytotoxicity of cytotoxic T lymphocytes to ovarian carcinoma cells.

Authors:  Xinyan Wang; Yu Liang; Jun Wang; Min Wang
Journal:  Tumour Biol       Date:  2013-03-01

5.  Cyclooxygenase-2 inhibition and hypoxia-induced pulmonary hypertension: effects on pulmonary vascular remodeling and contractility.

Authors:  Laura E Fredenburgh; Jun Ma; Mark A Perrella
Journal:  Trends Cardiovasc Med       Date:  2009-02       Impact factor: 6.677

6.  Selective COX-2 inhibitor celecoxib combined with EGFR-TKI ZD1839 on non-small cell lung cancer cell lines: in vitro toxicity and mechanism study.

Authors:  Likun Chen; Youjian He; He Huang; Hai Liao; Weidong Wei
Journal:  Med Oncol       Date:  2008-01-03       Impact factor: 3.064

7.  Cyclooxygenase-2 selective inhibition with NS-398 suppresses proliferation and invasiveness and delays liver metastasis in colorectal cancer.

Authors:  M Yao; E C Lam; C R Kelly; W Zhou; M M Wolfe
Journal:  Br J Cancer       Date:  2004-02-09       Impact factor: 7.640

8.  Dioscorea japonica extract down-regulates prostaglandin E2 synthetic pathway and induces apoptosis in lung cancer cells.

Authors:  Toshiko Suzuki-Yamamoto; Sayuri Tanaka; Izumi Tsukayama; Miki Takafuji; Takae Hanada; Toshiya Arakawa; Yuki Kawakami; Masumi Kimoto; Yoshitaka Takahashi
Journal:  J Clin Biochem Nutr       Date:  2014-09-09       Impact factor: 3.114

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.